This study aimed to provide an interim evaluation of the combination of androgen receptor signaling inhibitors denosumab, LRT, and metastasis‐directed therapy (MDT) for prostate cancer with multiple bone metastases (poly‐PCa). The gene discussed is AR; the disease is prostate cancer.